Willingness of injection drug users to participate in an HIV vaccine efficacy trial in Bangkok, Thailand

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 3, 1999, Pages 243-251

  MacQueen, Kathleen M ^a,f   Vanichseni, Suphak ^b   Kitayaporn, Dwip ^c,d   Lin, Lillian S ^a   Buavirat, Aumphornpun ^b   Naiwatanakul, Thananda ^d   Raktham, Suwanee ^b   Mock, Philip ^d   Heyward, William L ^a   Des Jarlais, Don C ^e   Choopanya, Kachit ^b   Mastro, Timothy D ^a,d  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Bangkok Metropolitan Administration   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d HIV/AIDS Collaboration   (Thailand)

^e BETH ISRAEL MEDICAL CENTER   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Attitudes; Drug users; HIV 1; Knowledge; Thailand; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; ATTITUDE; CLINICAL TRIAL; COMPREHENSION; COOPERATION; DECISION MAKING; DRUG EFFICACY; DRUG RESEARCH; FEMALE; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; THAILAND;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0033166971     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-199907010-00010     Document Type: Article

References (22)

1. Mastro TD, Kitayaporn D, Weniger BG, et al. Estimating the number of HIV-infected injection drug users in Bangkok: a capture-recapture method. Am J Public Health 1994;84:1094-9.
2. Choopanya K, Vanichseni S, Des Jarlais DC, et al. Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS 1991;5:1509-13.
3. Ministry of Public Health. AIDS surveillance report, Thailand. Wkly Epidemiol Surveill Rep (Thailand) 1993;24:13-29.
4. Vanichseni S, Kitayaporn D, Mastro TD, et al. HIV-1 incidence, subtypes, and follow-up in a prospective cohort of injecting drug users (IDUs) in Bangkok, Thailand [abstract #13127]. XII World AIDS Conference, Geneva, Switzerland, 1998.
5. Ou CY, Takebe Y, Weniger BG, et al. Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand. Lancet 1993;342:1171-4.
6. Weniger BG, Takebe Y, Ou CY, Yamazaki S. The molecular epidemiology of HIV in Asia. AIDS 1994;8(Suppl 2):S13-28.
7. Wasi C, Herring B, Raktham S, et al. Determination of HIV-1 subtypes in injecting drug users in Bangkok, Thailand, using peptide binding enzyme immunoassay and the heteroduplex mobility assay: evidence of increasing infection with HIV-1 subtype E. AIDS 1995;9:843-9.
8. Subbarao S, Vanichseni S, Mastro TD, et al. Genetic characterization of incident HIV-1 subtype B and E strains from injecting drug users (IDUs), Bangkok, Thailand [abstract #13133]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
9. Kitayaporn D, Vanichseni S, Mastro TD, et al. Infection with HIV-1 subtypes B and E in injecting drug users screened for enrollment into a prospective cohort in Bangkok, Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:289-95.
10. Lurie P, Bishaw M, Chesney M, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. JAMA 1994;271:295-301.
11. Porter J, Glass M. Ethical considerations in AIDS vaccine testing. IRB: Rev Hum Subjects Res 1989;11:1-4.
12. U.S. Congress, Office of Technology Assessment. Adverse reactions to HIV vaccines: medical, ethical, and legal issues. Report No. OTA-BP-H-163. Washington, DC: U.S. Government Printing Office, 1995.
13. Agresti A. Categorical data analysis. New York: John Wiley and Sons, 1990:322-31.
14. Breslow NE, Day NE. Unconditional logistic regression for large strata. In Davis W, ed. Statistical methods in cancer research: the analysis of case-control studies, vol 1. Lyons: IARC Scientific Publications, 1980:221-4.
15. Harrison K, Vlahov D, Jones K, Charron K, Clements ML. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for a HIV vaccine trial. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:386-90.
16. Celentano DD, Beyrer C, Natpratan C, et al. Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. AIDS 1995;9:1079-83.
17. Meyers K, Metzger DS, Navaline H, Woody OE, McLellan AT. HIV vaccine trials: will intravenous drug users enroll? Am J Public Health 1994;84:761-6.
18. Bartholow BN, MacQueen KM, Douglas JM, Buchbinder S, McKirnan D, Judson FN. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:108-15.
19. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate ! in HIV vaccine efficacy trials in the United States. AIDS 1998;12: 785-93.
20. Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:266-71.
21. Hiranras K, Vanichseni S, Kitayaporn D, et al. Incarceration as a continuing HIV risk factor among injecting drug users in Bangkok, Thailand [poster #23209]. Presented at the XII World AIDS Conference, Geneva, Switzerland, 1998.
22. MacQueen KM, Buchbinder S, Douglas JM, Judson FN, McKirnan DJ, Bartholow B. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses 1994;10(Suppl 2):S261-4.